Clinical Trial Update: A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial evaluating CAR T-cell therapy for relapsed or refractory hematologic malignancies, including lymphoma and leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Snippet

Sponsor: Affiliated Hospital of Nantong University | Conditions: Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia | EARLY_Phase 1 | Status: RECRUITING